Primary Adult Renal Ewing's Sarcoma: A Rare Entity

Table 1

Treatment and outcome in the seven patients with primary renal Ewing’s sarcoma.

(a) Patients without metastatic disease at presentation

Age in years	Year of diagnosis	Sex	Side of renal primary	Radical nephrectomy	chemotherapy	Site of relapse	Disease-free interval in months	Status at last follow up	Survival in months
50	1993	Male	Left	Yes	4 VID/2 IE	No relapse	149.7	Alive (no disease)	149.7
34	2000	Male	Right	Yes	3 CVD/3 EP	Lung	55.4	Alive (stable disease)	107.4
57	2007	Female	Left	Yes	1 VAC	Liver, spleen	5.3	Died (progressive disease)	6.5
43	2007	Male	Left	Yes	4MVAC > 2VIDE > 3VAD	Bone	5.1	Alive (stable disease)	15.6

(b) Patients with metastatic disease at presentation

Age in years	Year of diagnosis	Sex	Side of renal primary	Radical nephrectomy	Metastatic site at presentation	chemotherapy	Time to disease progression in months	Status at last follow up	Survival in months
35	1997	Female	Left	No	Liver, node	3 PD/3ID	24	Died (progressive disease)	62.8
32	1999	Female	Right	No	Liver, node	Etoposide	0	Died (progressive disease)	26.5
50	2007	Male	Left	No	Liver, adrenal	4VIDE > 6VAC	12	Died (progressive disease)	13.1

Abbreviations: V: vincristine (vinblastine in MVAC), P: cisplatin, I: ifosfamide, D: doxorubicin, E: etoposide, A: actinomycin D (doxorubicin in IVAD).